Curis forms $25 million deal with Aegera:
This article was originally published in Clinica
Executive Summary
Tissue regeneration company Curis has gained an exclusive licensing and research agreement with Aegera Therapeutics for its skin-derived, adult stem cell technologies. The deal, which is valued at over $25 million, involves research into the potential use of the technologies for neurological, pancreatic and cardiovascular disorders. Research will be carried out by Cambridge, Massachusetts-based Curis, Aegera, of Montreal, and McGill University in Montreal.